What Health Claims Can You Make in Japan? FFC, FOSHU, and the Rules

Japan's health claim framework

Japan has one of the world's most sophisticated — and most strictly enforced — health claim frameworks. Unlike the US, where disclaimer-based structure/function claims are relatively easy to make, Japan requires either notification with evidence or formal approval for any functional health claim.

Three legitimate pathways exist for health-related claims on food and supplement products. Choosing the right one depends on your product category, the specific claim you want to make, and how quickly you need to reach market.

Foods with Nutrient Function Claims (FNFC)

FNFC is the simplest pathway. Products that contain specified nutrients within approved quantity ranges can automatically use standardized nutrient function claims — no notification required.

FNFC claims must use the exact standardized Japanese-language text. Paraphrasing or adapting the approved claim text is not permitted.

Foods with Function Claims (FFC)

Introduced in 2015, the FFC system allows manufacturers to make specific functional health claims after notifying the Consumer Affairs Agency (CAA) and receiving a registration number. This is the most flexible pathway for supplement brands with evidence-backed functional claims.

FFC claims must be: supported by a systematic review of published research or a human clinical trial, specific to a named body part or function (not disease treatment), and submitted to CAA at least 60 days before product sale.

The CAA publishes all FFC notifications in a public database. Reviewing approved FFC claims in your category is a useful way to understand what Japan's regulators have accepted from comparable products.

Foods for Specified Health Uses (FOSHU)

FOSHU is the premium health claim category — the Japanese equivalent of a full health claim approval. FOSHU products carry an official government seal and can make approved health benefit statements directly tied to the product's effect on specific health outcomes.

FOSHU approval requires formal review and approval by MHLW, supported by clinical evidence. The approval process typically takes 12-24 months and involves significant regulatory cost. FOSHU is appropriate for established brands with strong clinical evidence and long-term Japan market ambitions — not for most initial market entry strategies.

Claims that trigger pharmaceutical classification

The following types of claims will trigger pharmaceutical classification regardless of which health claim pathway you are using:

• Any reference to disease treatment, diagnosis, prevention, or cure
• Claims that imply modification of body structure or function beyond normal nutritional support
• Before/after comparisons suggesting therapeutic effect
• Specific physiological mechanism claims (e.g., "inhibits enzyme X," "stimulates hormone Y")
• Claims referencing specific medical conditions — even in indirect form

Marketing language used in the US or Australia frequently contains phrases that would trigger pharmaceutical classification in Japan. A label and marketing copy review against Japanese standards is essential before launch.